Gynecologic Cancer,Ovarian Cancer Pros in the Mirasol and Forward I Trial on the Effect of MIRV in the Treatment of PROC Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Olaparib vs. Non-Platinum Chemotherapy for PSROC with BRCA1/2 Mutations Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Maintenance Olaparib in PSROC: Safety and Efficacy Regardless of BRCA Status Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Viability of Rucaparib for Recurring Ovarian Cancer: A Study Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer 7-Year Follow-Up: Olaparib as First-Line for Advanced Ovarian Cancer Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Efficacy of First-Line Rucaparib Maintenance for Ovarian Cancer by Disease Risk Subgroups Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer BOOST Phase III Trial: Optimal Duration of Bevacizumab for Ovarian Cancer Mar 27, 2023
Gynecologic Cancer,Ovarian Cancer VELIA Trial: Veliparib as Maintenance Therapy for Frontline Ovarian Cancer Mar 27, 2023
